REGN vs TEVA: stock comparison and AI forecast
Regeneron Pharmaceuticals, Inc. (REGN) and Teva Pharmaceutical Industries Ltd (TEVA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
REGN Regeneron Pharmaceuticals, Inc.
- Price
- $961.26 +35.5% · 6M
- Market Cap
- $100.21B
- P/E Ratio
- 21.6x
- Size
- large-cap
- AI Forecast
TEVA Teva Pharmaceutical Industries Ltd
- Price
- $40.70 +15.1% · 6M
- Market Cap
- $47.43B
- P/E Ratio
- 84.8x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- REGN is 2.1 times larger than TEVA by market capitalization ($100.21B against $47.43B).
- REGN trades at 21.6 times trailing earnings, TEVA at 84.8 times.
- Over the last six months REGN returned +35.5% and TEVA +15.1%.
- TEVA turns 45.4% of its revenue into net income, against 36.5% for REGN.
- TEVA carries 4.14 times debt per unit of equity, against 0.33 times for REGN.
- REGN yields 0.38% in dividends; TEVA pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | REGN | TEVA |
|---|---|---|
| Market Cap | $100.21B | $47.43B |
| P/E Ratio | 21.55x | 84.79x |
| P/B Ratio | 2.99x | 6.12x |
| Dividend Yield | 0.38% | – |
| EPS | $45.18 | $0.48 |
| Book Value/Share | $325.37 | $6.65 |
| Revenue/Share | $164.11 | $1.34 |
| FCF/Share | $37.16 | $1.16 |
Profitability & Margins
| Metric | REGN | TEVA |
|---|---|---|
| ROE | 18.4% | 9.1% |
| ROA | 13.9% | 1.8% |
| ROIC | 12.7% | 6.6% |
| Gross Margin | – | -428.7% |
| Operating Margin | 28.8% | 103.0% |
| Net Margin | 36.5% | 45.4% |
| EBT Margin | 33.6% | 46.4% |
| Tax Rate | 15.3% | 1.7% |
Financial Health
| Metric | REGN | TEVA |
|---|---|---|
| Current Ratio | 3.35x | 0.88x |
| Quick Ratio | 2.89x | 0.67x |
| D/E Ratio | 0.33x | 4.14x |
| Financial Leverage | 1.33x | 5.14x |
| Interest Coverage | 21.1x | 0.3x |
| Working Capital | $14.59B | -$1.89B |
Cash Flow
| Metric | REGN | TEVA |
|---|---|---|
| Operating Cash Flow | $4.85B | $1.90B |
| Free Cash Flow | $3.83B | $1.35B |
| Capital Spending | -$1.02B | -$550M |
| OCF Growth YoY | -4.4% | 36.5% |
| FCF Growth YoY | -9.4% | 51.5% |
| FCF/Sales | 22.6% | 86.6% |
| CapEx/Sales | 6.0% | 35.3% |
Operational Efficiency
| Metric | REGN | TEVA |
|---|---|---|
| Asset Turnover | 0.38x | 0.04x |
| Receivables Turnover | 2.2x | 0.5x |
| Inventory Turnover | – | 2.6x |
| Fixed Assets Turnover | 3.0x | 0.4x |
| Days Sales Outstanding | 164 days | 819 days |
| Days Inventory | – | 143 days |
Income Statement
| Metric | REGN | TEVA |
|---|---|---|
| Total Revenue | $16.90B | $1.56B |
| Operating Income | $4.86B | $1.60B |
| Net Income | $6.17B | $707M |
| R&D Expense | $6.60B | $1.49B |
| SG&A Expense | $2.76B | $4.46B |
| Cost of Goods Sold | – | $8.23B |
Dividend & Shareholder Information
| Metric | REGN | TEVA |
|---|---|---|
| Dividends Per Share | $3.72 | – |
| Payout Ratio | 8.2% | – |
| Shares Outstanding | 103M | 1165M |
| Net Income Growth | 220.3% | – |
| EPS Growth | 8.0% | – |
REGN vs TEVA: stock comparison and AI forecast
Which is bigger, REGN or TEVA?
REGN is 2.1 times larger than TEVA by market capitalization ($100.21B against $47.43B).
Which is cheaper on earnings, REGN or TEVA?
REGN trades at 21.6 times trailing earnings, TEVA at 84.8 times.
Which stock performed better over the last six months, REGN or TEVA?
Over the last six months REGN returned +35.5% and TEVA +15.1%.
Which one does Intratio's AI model rank higher, REGN or TEVA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.